title: Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
abstract: In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.
authors: Department of Internal Medicine, School of Medicine, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, Virginia, USA. paessah@comcast.net
authors: Paulina A
authors: PA
authors: Essah
authors: James A
authors: JA
authors: Arrowood
authors: Kai I
authors: KI
authors: Cheang
authors: Swati S
authors: SS
authors: Adawadkar
authors: Dale W
authors: DW
authors: Stovall
authors: John E
authors: JE
authors: Nestler
mesh_terms: D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage*; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage*; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D018836:Inflammation Mediators / Q000097:blood; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008687:Metformin / Q000008:administration & dosage*; D009644:Norgestrel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D050177:Overweight / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D015990:Placebo Effect; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects; D014768:Virginia
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D004338:Drug Combinations; D012739:Gonadal Steroid Hormones; D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D007328:Insulin; D008055:Lipids; C109079:norgestimate, ethinyl estradiol drug combination; D009644:Norgestrel; D004997:Ethinyl Estradiol; D008687:Metformin